Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
BeOne Medicines discovers and develops oncology treatments for cancer patients around the world.
BeOne Medicines is a cancer drug company. It discovers and develops medicines for people fighting cancer, and it sells those treatments in the United States, China, Europe, and other markets. Its business is built on the long, expensive, high-stakes hunt for therapies that shrink tumors or help patients live longer.
Its best-known product is Brukinsa, a pill for certain blood cancers. Brukinsa is the company's engine: it competes directly with AbbVie's Imbruvica and others, and it has grown fast enough to become a major revenue driver in the U.S. and abroad. The company also sells older, well-established drugs, most notably in China, where it has deep roots and a large commercial operation. Those products throw off cash and funding that help pay for the risky work of developing new medicines. The economics of this business are unusual. Developing a cancer drug can take a decade and cost billions, and most candidates fail. A company wins by getting a drug approved, then charging high prices while it is protected by patents. When patents expire, cheap generics copy the drug and revenue collapses. So BeOne constantly needs new products in the pipeline to replace the old ones, and it spends heavily on research and clinical trials. It also relies on deals鈥攑artnering with other firms or buying assets鈥攖o fill its pipeline.
The company's history helps explain its shape. It began as BeiGene, founded by a Chinese-American scientist and backed by U.S. and Chinese investors, and it grew into a global player with a dual listing in Hong Kong and on the Shanghai exchange before adding a U.S. listing. It sold a large stake to Amgen, and later rebranded as BeOne Medicines with a Swiss base to signal a more global identity. Its recent profitability, driven mostly by Brukinsa, is the key thing to watch: if that drug keeps growing, the company has room to fund its next wave of medicines. If competition or pricing pressure bites, the pipeline has to carry more weight.
Saved answer 路 last researched 12 Nov 2026